Eczema Treatments After Dupixent: What Are the Alternatives?

Published March 2026 · 8 min read

Medically reviewed by licensed healthcare professionals · Legally reviewed by mass tort litigation specialists · Last updated: March 2026

Patients may stop taking Dupixent for a variety of reasons: persistent side effects like conjunctivitis, a perceived lack of effectiveness over time, insurance coverage changes, or concerns about long-term safety signals like malignancy risk. The decision to stop any prescribed therapy should always be made in consultation with a physician. This guide outlines the main alternative treatment categories that doctors and patients typically discuss after Dupixent.

Important First Step: Do Not Stop Abruptly

Before considering alternatives, it's critical to have a transition plan with your doctor. Abruptly stopping Dupixent can lead to a rebound flare of atopic dermatitis, which can be severe. Your physician can help you taper off the medication or bridge to a new therapy in a way that minimizes the risk of a major symptom return. This is not just a medical issue; documenting a physician-supervised transition is also important for any potential legal claim, as it demonstrates that you followed medical advice.

Alternative Biologics for Atopic Dermatitis

While Dupixent was the first biologic approved for atopic dermatitis, other options that target different immune pathways are now available.

Tralokinumab (Adbry): Like Dupixent, Adbry is an injectable monoclonal antibody. However, it specifically targets IL-13, one of the two cytokines blocked by Dupixent. For some patients, this more targeted mechanism may offer a different balance of efficacy and side effects. It is generally considered to have a similar safety profile to Dupixent.
Lebrikizumab: Another IL-13 inhibitor, lebrikizumab is in the same class as Adbry and offers another alternative for patients who may not have responded optimally to Dupixent.

For patients switching from one biologic to another, physicians will typically plan for a "washout" period or a direct transition depending on the specific drugs and the patient's clinical situation.

Oral JAK Inhibitors

Janus kinase (JAK) inhibitors are a newer class of oral medications (pills, not injections) that offer a different mechanism of action for moderate-to-severe atopic dermatitis.

Upadacitinib (Rinvoq): An oral JAK inhibitor approved for atopic dermatitis. It has shown high efficacy but comes with a Boxed Warning from the FDA for risks including serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis (blood clots).
Abrocitinib (Cibinqo): Another oral JAK inhibitor with a similar efficacy and safety profile to Rinvoq, including the same Boxed Warning.

The decision to switch to a JAK inhibitor after Dupixent is a significant one. While they can be highly effective, the Boxed Warnings mean they carry a different and, in some respects, more serious risk profile. This is a conversation that requires a thorough review of your personal medical history, particularly any history of cancer, heart disease, or blood clots.

Traditional Systemic Immunosuppressants

Before the era of biologics, severe atopic dermatitis was often treated with broader systemic immunosuppressants. These are generally less favored now due to their side effect profiles, but they remain an option in some cases.

Cyclosporine: A potent immunosuppressant that is effective for severe eczema but carries risks of kidney damage and high blood pressure with long-term use. It is typically used for short-term control of severe flares.
Methotrexate: An immunomodulator often used in psoriasis and rheumatoid arthritis, it is sometimes used off-label for atopic dermatitis. It requires regular blood monitoring to check for liver toxicity.
Azathioprine and Mycophenolate Mofetil: Other immunosuppressants that may be considered in refractory cases.

Phototherapy (Light Therapy)

Phototherapy involves controlled exposure to ultraviolet (UV) light, typically narrowband UVB, administered in a dermatologist's office 2-3 times per week. It can be very effective for controlling atopic dermatitis by reducing inflammation in the skin.

Pros: Avoids systemic side effects of drugs, can be highly effective.
Cons: Time-consuming due to frequent office visits, potential for skin burning, and a long-term increased risk of skin cancer (though this is more associated with older broadband UVB and PUVA therapies).

Topical Therapies

For patients stepping down from a systemic therapy like Dupixent, optimizing topical treatments is key. This may involve:

High-potency topical steroids: Used for short durations to control flares.
Topical calcineurin inhibitors (e.g., Protopic, Elidel): Non-steroidal options for sensitive areas like the face and skin folds.
Topical JAK inhibitors (Opzelura): A topical version of a JAK inhibitor that can be effective for localized eczema without the systemic risks of the oral versions.
Crisaborole (Eucrisa): A non-steroidal topical ointment that works by a different mechanism (PDE4 inhibition).

Documenting Your Transition

If you are stopping Dupixent due to safety concerns and are considering a legal claim, it is vital to document the transition process. Keep records of your conversations with your doctor about why you are stopping the drug. Track your symptoms during and after the transition. Preserve records of the new therapies you start and how you respond to them. This creates a clear medical narrative that connects your decision to stop Dupixent to a specific safety concern and documents the subsequent medical journey, all of which is relevant to a potential legal claim.